Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NPH human insulin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| insulin glargine | DRUG | - |
| NPH human insulin | DRUG | - |
Inclusion Criteria: * Insulin naïve subjects with type 2 diabetes treated with oral hypoglycemic agents * Body mass index between 26 and 40 kg/m2 * HbA1c between 7.5% and 10.0% * Fasting plasma glucose \>7.8 mmol/L and fasting C-peptide \> or =0.25 nmol/L
NPH human insulin is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is an intermediate-acting insulin that helps control blood sugar levels in patients with this condition. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
NPH human insulin is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this insulin product for the management of Type 2 diabetes.
NPH human insulin is currently in Phase 3 clinical development. This stage involves large-scale studies to confirm the drug's effectiveness, monitor side effects, and compare it with commonly used treatments. The drug is still investigational and has not received regulatory approval for commercial use.
NPH human insulin has been studied in one completed Phase 3 clinical trial with the identifier NCT00653341. This trial, titled 'Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)', enrolled 764 participants across the United States and Canada. The study was completed and did not use a control group.
No, NPH human insulin and insulin glargine are different products. The clinical trial NCT00653341 compared the effects of insulin glargine in insulin-naïve patients with Type 2 diabetes, but NPH human insulin itself is a separate investigational drug being developed by Sanofi. They are not the same medication.